Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/ CSF1R signaling abnormalities in the cell line GDM1

Leukemia

Volumn 23, Issue 2, 2009, Pages 358-364

  Chase, A ^a   Schultheis, B ^b   Kreil, S ^a   Baxter, J ^a   Hidalgo Curtis, C ^a   Jones, A ^a   Zhang, L ^a   Grand, F H ^a   Melo, J V ^b,c   Cross, N C P ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BCR ABL PROTEIN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; IMATINIB; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; DRUG MECHANISM; EXON; GENE ACTIVATION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EID: 60149102247     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.295     Document Type: Article

References (32)

1. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
2. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001; 97: 2440-2448.
3. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127-3132.
4. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105 2640-2653.
5. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30: 965-970.
6. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R et al. Durable responses to Imatinib in patients with PDGFRB fusion gene positive and BCR-ABL negative chronic myeloproliferative disorders. Blood 2007; 109: 61-64.
7. Drexler H. The Leukemia-Lymphoma Cell Line Facts Book. Academic Press: San Diego, CA, 2000.
8. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
9. Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Galli A et al. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia 2007; 21: 397-402.
10. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV et al. A novel K509I mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006; 30: 373-378.
11. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20: 827-832.
12. Heath C, Cross NC. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. J Biol Chem 2004; 279: 6666-6673.
13. Dibb NJ, Green SM, Ralph P. Expression of v-fms and c-fms in the hemopoietic cell line FDC-P1. Growth Factors 1990; 2: 301-311.
14. Hawley RG, Lieu FH, Fong AZ, Goldman SJ, Leonard JP, Hawley TS. Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect. Ann NY Acad Sci 1996; 795: 341-345.
15. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
16. Beghini A, Magnani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: A t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002; 3: 157-163.
17. Nagel S, Kaufmann M, Scherr M, Drexler HG, MacLeod RA. Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1). Genes Chromosomes Cancer 2005; 42: 170-178.
18. Baker DA, Glover HR, Dibb NJ. Synergy between SCF or M-CSF with IL-3 or GM-CSF in FDC-P1 cells: A sensitive assay of transforming mutations of c-fms. Leukemia 1994; 8: 141-150.
19. Glover HR, Baker DA, Celetti A, Dibb NJ. Selection of activating mutations of c-fms in FDC-P1 cells. Oncogene 1995; 11: 1347-1356.
20. Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008; 111: 4809-4812.
21. Abu-Duhier FM, Goodeve AC, Care RS, Gari M, Wilson GA, Peake IR et al. Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol 2003; 120: 464-470.
22. Abu-Duhier FM, Goodeve AC, Wilson GA, Peake IR, Reilly JT. c-FMS mutational analysis in acute myeloid leukaemia. Br J Haematol 2003; 123: 749-750.
23. van Daalen WT, Hawkins SA, Roussel MF, Sherr CJ. Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain. EMBO J 1992; 11: 551-557.
24. Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 2007; 110: 323-333.
25. Ben-Bassat H, Korkesh A, Voss R, Leizerowitz R, Polliack A. Establishment and characterization of a new permanent cell line (GDM-1) from a patient with myelomonoblastic leukemia. Leuk Res 1982; 6 743-752.
26. Walter M, Lucet IS, Patel O, Broughton SE, Bamert R, Williams NK et al. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 2007; 367: 839-847.
27. Li S, Covino ND, Stein EG, Till JH, Hubbard SR. Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor. J Biol Chem 2003; 278: 26007-26014.
28. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001; 106: 745-757.
29. Myles GM, Brandt CS, Carlberg K, Rohrschneider LR. Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization. Mol Cell Biol 1994; 14: 4843-4854.
30. Irusta PM, Luo Y, Bakht O, Lai CC, Smith SO, DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem 2002; 277: 38627-38634.
31. Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: Oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 2004; 4: 718-727.
32. Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12: 501-513.